Standout Papers
Citation Impact
Citing Papers
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis
2007 Standout
Imitators of Severe Pre-eclampsia
2009
Thrombolysis for pulmonary embolism
1991
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
1992
A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk
2005
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
1998 Standout
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
2004
Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype
2007 StandoutNobel
Role of the macrophage in erythropoiesis
1999
Novel droplet platforms for the detection of disease biomarkers
2014
Thymus, innate immunity and autoimmune arthritis: Interplay of gene and environment
2011 StandoutNobel
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Oral Anticoagulant Therapy
2012 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin
2006
The dynamic disulphide relay of quiescin sulphydryl oxidase
2012 StandoutNatureNobel
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Tissue-resident macrophages
2013 Standout
The Molecular Genetics of Crop Domestication
2006 Standout
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
2005
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes
2010
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
2005
Vascular disorders of the liver # †
2008 Standout
Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9
2005
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation
2005
Reteplase in the Treatment of Peripheral Arterial and Venous Occlusions: A Pilot Study
2000
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
Pharmacogenomics: Challenges and Opportunities
2006
Genetic and clinical factors relating to warfarin dosing
2009
The Missing Diversity in Human Genetic Studies
2019 Standout
CTLA4 promoter and exon 1 dimorphisms in multiple sclerosiso
1999
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
2005
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism
1999
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
2009
Prevention of Venous Thromboembolism
2004 Standout
A new high-performance liquid chromatographic method for determination of warfarin enantiomers
2005 StandoutNobel
Pre-eclampsia
2010 Standout
A genotyping method for VKORC1 1173C>T by Pyrosequencing®technology
2008 StandoutNobel
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Selective sweep mapping of genes with large phenotypic effects
2005
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
The vitamin K cycle
2005
Prevention of Venous Thromboembolism
2008 Standout
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion
2001
The pathophysiology and management of thrombotic thrombocytopenic purpura
1996
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Idiopathic pulmonary fibrosis
2011 Standout
A genome-wide association study of acenocoumarol maintenance dosage
2009
A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism
1990
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
2009
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Understanding the genetic contribution to rheumatoid arthritis
2005
Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation
2002
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
2008
Vitamin K epoxide reductase: homology, active site and catalytic mechanism
2004
haplotype structure in European American warfarin patients and association with clinical outcomes
2005
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
2006
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records
2006 StandoutNobel
Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Thromboprophylaxis in Patients With Cancer<subtitle>A Systematic Review and Meta-analysis</subtitle>
2008
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
2005
Heparins and mechanical methods for thromboprophylaxis in colorectal surgery
2003
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
No Effect of Clot Age or Thrombolysis on Argatroban’s Inhibition of Thrombin
1998
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Catheter-Directed Thrombolytic Therapy in Peripheral Artery Occlusions: Combining Reteplase and Abciximab
2003
Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans
2008
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
2005
Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats
2006
Harnessing host–virus evolution in antiviral therapy and immunotherapy
2019
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
2005
Guidelines for the Primary Prevention of Stroke
2014 Standout
The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement
2006
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2010 Standout
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice
2002 StandoutNobel
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment
2016
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
2009
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
2017
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
2007
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease
2013
Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners
2010
Polycythemia vera: myths, mechanisms, and management
2002
Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
2014
CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
2009
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
2013 Standout
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Development of a Point of Care Lateral Flow Device for Measuring Human Plasma Fibrinogen
2010 StandoutNobel
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Emerging Droplet Microfluidics
2017 Standout
Vascular Calcification
2008 Standout
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
2004
Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery
2001
A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) ina patient on warfarin therapy
2006
Works of E. Seifried being referenced
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation
2005
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
2004 StandoutNature
Effect of reteplase on hemostasis variables: analysis of fibrin specifity, relation to bleeding complications and coronary patency
1998
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction
1992
Protection against severe disease is conferred by DERAA-bearing HLA-DRB1 alleles among HLA-DQ3 and HLA-DQ5 positive rheumatoid arthritis patients
2001
Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis
1994
Budd-chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases
1989
Studies on the functionality of fibrinogen during rt-PA therapy
1992
Thrombotic thrombocytopenic purpura in early pregnancy with maternal and fetal survival
1992
Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction
1989
CTLA4 gene haplotypes cannot protect from IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families.
1998
Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism
1992
Hematologic effects of recombinant human interleukin-6 in dogs exposed to a total-body radiation dose of 2.4 Gy.
1994